The development of health technology assessment

Banta, David

doi:10.1016/s0168-8510(02)00059-3

Cited by 257 publications

(196 citation statements)

References 21 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Health Technology Assessment (HTA) is basically concerned with a systematic analysis and synthesis of the available evidence of clinical and cost effectiveness of medical technologies to support healthcare policy decision-making. In a number of countries, economic evaluation is a central focus of HTA [15][16][17][18][19]. Economic evaluation with early data is relevant as HTA is often applied to new technologies about to diffuse, playing an important role for decisions on medical innovations as it links the evaluation of evidence to policy making and application in practice.…”

Section: Health Technology Assessment -A Framework For the Evidence-bmentioning

confidence: 99%

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Hartz

John

2009

Health Policy

View full text Add to dashboard Cite

Standard-Nutzungsbedingungen:Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte. Terms of use: Documents in

show abstract

Section: Health Technology Assessment -A Framework For the Evidence-bmentioning

confidence: 99%

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Hartz

John

2009

Health Policy

View full text Add to dashboard Cite

show abstract

“…These differences are inevitable due to the complexity of these processes and the context within which they operate, where each country sets its own objectives for conducting HTA reflecting its values, preferences and constraints [2][3][4]. Implications include uneven access to these medicines across (often neighbouring) countries, non-optimal use of healthcare resources, and the unpredictability of the pharmaceutical market.…”

Section: Introductionmentioning

confidence: 99%

Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study

Nicod

Kanavos

2016

Health Policy

View full text Add to dashboard Cite

Original citation:Nicod, Elena and Kanavos, Panos (2016) Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: a mixed methods study. Health Policy, 120 (1). pp. 35-45. ISSN 0168-8510 DOI: 10.1016/j.healthpol.2015 Reuse of this item is permitted through licensing under the Creative Commons: a b s t r a c tHealth Technology Assessment (HTA) often results in different coverage recommendations across countries for a same medicine despite similar methodological approaches. This paper develops and pilots a methodological framework that systematically identifies the reasons for these differences using an exploratory sequential mixed methods research design. The study countries were England, Scotland, Sweden and France. The methodological framework was built around three stages of the HTA process: (a) evidence, (b) its interpretation, and (c) its influence on the final recommendation; and was applied to two orphan medicinal products. The criteria accounted for at each stage were qualitatively analyzed through thematic analysis. Piloting the framework for two medicines, eight trials, 43 clinical endpoints and seven economic models were coded 155 times. Eighteen different uncertainties about this evidence were coded 28 times, 56% of which pertained to evidence commonly appraised and 44% to evidence considered by only some agencies. The poor agreement in interpreting this evidence (Ä = 0.183) was partly explained by stakeholder input (n s = 48 times), or by agency-specific risk (n u = 28 uncertainties) and value preferences (n oc = 62 "other considerations"), derived through correspondence analysis. Accounting for variability at each stage of the process can be achieved by codifying its existence and quantifying its impact through the application of this framework. The transferability of this framework to other disease areas, medicines and countries is ensured by its iterative and flexible nature, and detailed description.

show abstract

“…O uso da evidência científica A aplicação da evidência científica na prática clínica, com o objetivo de melhorar a qualidade e a efetividade do cuidado individual ao paciente, é referenciada como Medicina Baseada em Evidências (MBE). A prática da MBE integra a experiência clínica individual, a perícia médica individual das circunstâncias de atendimento (situação local e particularidades dos doentes) e os desejos do doente com a melhor avaliação de evidência clínica externa a partir de pesquisa sistemática (BANTA, 2003;CORDEIRO et al, 2007, OTTOLENGHI, 2002COCHRANE, 2008). Para tal, a MBE utiliza dos princípios da Avaliação Tecnológica em Saúde.…”

Section: Segurança Sanitáriaunclassified

Um enfoque sanitário sobre a demanda judicial de medicamentos

Figueiredo

Pepe

Osório-de-Castro³

2010

Physis

View full text Add to dashboard Cite

No Brasil, apesar dos avanços da assistência farmacêutica, permanecem falhas na garantia do acesso dos cidadãos aos medicamentos pelo Estado. Nos últimos anos, vem crescendo a reivindicação de medicamentos por parte do cidadão via sistema judiciário. Os objetos dessas solicitações são tanto os medicamentos em falta na rede pública como aqueles ainda não incorporados pelo Sistema Único de Saúde. Este fenômeno pode ser analisado sob diferentes perspectivas, inclusive a sanitária, entendida aqui como os desfechos sobre a saúde dos indivíduos que demandam estes medicamentos. O presente texto busca discutir as principais características das demandas judiciais frente aos seguintes aspectos: o uso racional de medicamentos, o uso de evidências científicas para a indicação terapêutica proposta e o quanto as demandas se justificam diante do conceito de acesso adotado pelo campo da assistência farmacêutica. Ponderações podem ser feitas no sentido de minimizar os riscos à saúde dos demandantes de medicamentos por via judicial, sobretudo quando o objeto da ação são medicamentos não pertencentes às listas de fornecimento público, ou com uso off label, ou desprovidos de registro no país. Considera-se que o Judiciário, a partir do fornecimento de medicamentos, busca garantir a saúde dos demandantes, e assim a dignidade da pessoa humana. Cabe ressaltar que este objetivo só será atingido quando a garantia da saúde estiver associada aos aspectos que certificam a segurança do paciente, inclusive no uso de medicamentos.

show abstract

The development of health technology assessment

Cited by 257 publications

References 21 publications

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study

Um enfoque sanitário sobre a demanda judicial de medicamentos

Contact Info

Product

Resources

About